BCCA Protocol Summary for Intravesical Therapy for Superficial Transitional Cell Bladder Cancer using Mitomycin

**Protocol Code**

GUBMITO

**Tumour Group**

Genitourinary

**Contact Physician**

Dr. Kim Chi

Dr. Peter Black

**ELIGIBILITY:**

- Transitional cell bladder cancer
- Post-transurethral resection

**TESTS:**

- No routine lab tests before each treatment

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
</table>
| mitomycin | 40 mg | Intravesically in 20 mL sterile water for injection
|         |      | Administer instillation via catheter (dwell time of 1 to 2 hours, patient to change position every 15 minutes) |

- **Induction:** weekly for 6 weeks
- **Maintenance:** monthly for 1 year, starting 6 weeks after end of induction (i.e., at 3 months)

**PRECAUTIONS:**

1. Patients should be advised to minimise oral fluids (especially those containing caffeine) for 6-8 hours before each treatment to minimise dilution of drug in the bladder.
2. Bladder irritation, with more frequent or painful urination, urination at night and some blood or tissue in the urine.

Call Dr. Kim Chi or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

**Date activated:** 1 October 2014

**Date revised:**

**Reference:**